High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)

Sponsor
Yigeng Cao,MD,PhD
Study ID
NCT07205523
Status
Recruiting
Apply to this trial

Conditions

  • Acute Myeloid Leukemia (AML)
  • Aplastic Anemia
  • Bleeding Disorders
  • Bone Marrow Transplantation
  • Hematopoietic Stem Cell Transplantation (HSCT)
  • Hemophilia
  • Immune Reconstitution
  • Leukemia
  • Leukemias, Acute Myeloid
  • Lymphoma
  • MDS
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloid Leukemias, Acute
  • Myeloma, Multiple

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Study Details

The High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) study is the first prospective real-world cohort of hematologic diseases and transplantation in the Qinghai-Tibet Plateau. Patients undergoing hematopoietic stem cell transplantation (HSCT) at Qinghai University Affiliated Hospital, together with their donors, are systematically enrolled. The registry collects demographic, diagnostic, treatment, prognosis, and medical expense information, as well as biospecimens for future analyses. Historical data are incorporated, and prospective data collection is ongoing with long-term follow-up planned. The registry is designed as a sustainable research infrastructure to provide comprehensive data on disease incidence, treatment patterns, outcomes, and resource utilization in a high-altitude setting.

Key Dates

First listed
Oct 3, 2025
Start date
Sep 1, 2023
Status verified
Sep 2025
Primary completion
Dec 31, 2060
Completion
Dec 31, 2100

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: HSCT Patients and Donors
    Patients undergoing hematopoietic stem cell transplantation (HSCT) at Qinghai University Affiliated Hospital, and their related or unrelated stem cell donors. Participants are prospectively followed for clinical outcomes and biospecimen collection under real-world conditions.

Primary Outcome Measure

Time to neutrophil engraftment [ Time Frame: From the date of HSCT until neutrophil engraftment or death, assessed up to 60 days ]

Central Contacts

Find similar trials

Nationwide
Leukemia (other) trialsMultiple myeloma trialsOncology trialsBlood cancer trials

Related Studies